Cyclobenzaprine (Flexeril) is a centrally-acting skeletal muscle relaxant, structurally related to tricyclic antidepressants, approved for short-term relief of acute muscle spasm — no more than 2–3 weeks. It acts on the brainstem to reduce abnormal motor neuron firing rather than directly relaxing muscle tissue. Common side effects include pronounced drowsiness, dry mouth, and dizziness. It is absolutely contraindicated with MAO inhibitors, causes dangerous CNS depression with alcohol or opioids, and is on the Beers Criteria as potentially inappropriate for elderly patients.
Cyclobenzaprine
Cyclobenzaprine is a centrally-acting skeletal muscle relaxant prescribed for the short-term relief of muscle spasms associated with acute musculoskeletal conditions. Structurally related to tricyclic antidepressants (TCAs), it shares many of their side effects and drug interactions while providing meaningful muscle relaxation through central nervous system mechanisms.
Uses & FDA Indications
Cyclobenzaprine is FDA-approved as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. It is intended for short-term use only — generally no more than 2 to 3 weeks. Evidence does not support its use for chronic musculoskeletal pain or spasticity from neurological conditions such as cerebral palsy or multiple sclerosis.
- Acute muscle spasm — back pain, neck pain, or other musculoskeletal injuries with painful spasm component
- Post-injury or post-surgery muscle tightness — as adjunctive treatment alongside physical therapy
- Off-label: fibromyalgia — some evidence supports use for sleep disturbance and pain in fibromyalgia
- Off-label: insomnia associated with pain — sedative properties used off-label in some patients
Cyclobenzaprine is not effective for muscle spasticity of central neurological origin (stroke, spinal cord injury, MS, cerebral palsy). It acts on brainstem pathways that modulate somatic motor activity — distinct from the spinal cord mechanisms that dominate upper motor neuron spasticity. Baclofen or tizanidine are more appropriate for that indication.
How It Works
Despite being classified as a muscle relaxant, cyclobenzaprine does not act directly on skeletal muscle fibers or the neuromuscular junction. Its mechanism is entirely central (brain and spinal cord).
Cyclobenzaprine acts primarily on the brainstem, reducing tonic somatic motor activity by influencing both alpha and gamma motor neurons. It is structurally very similar to tricyclic antidepressants (particularly amitriptyline), and like TCAs, it:
- Blocks norepinephrine reuptake, contributing to muscle relaxation via descending pain modulation pathways
- Antagonizes H1 histamine receptors — responsible for its prominent sedative effects
- Antagonizes muscarinic acetylcholine receptors — producing anticholinergic side effects (dry mouth, constipation, urinary retention)
- Has some 5-HT2 serotonin receptor antagonist activity
The result is reduced muscle hyperactivity and spasm through central inhibitory mechanisms, accompanied by significant sedation — which can itself aid recovery from acute injury by improving rest and sleep.
Side Effects
Common
- Drowsiness and sedation — the most reported side effect; affects the majority of patients
- Dry mouth — anticholinergic effect; very common
- Dizziness and lightheadedness
- Constipation
- Headache
- Blurred vision
- Fatigue and weakness
- Nausea
Serious
- Serotonin syndrome — risk exists when combined with serotonergic medications (SSRIs, MAOIs, tramadol, triptans); presents with agitation, hyperthermia, muscle rigidity, tachycardia
- Cardiac arrhythmias — due to TCA-like properties; can prolong QT interval, particularly in patients with pre-existing cardiac disease or at higher doses
- Urinary retention — anticholinergic effect; particularly problematic in men with enlarged prostate
- Severe CNS depression — confusion, disorientation, hallucinations (especially in elderly patients and with overdose)
- Acute angle-closure glaucoma — anticholinergic agents can precipitate this ocular emergency in predisposed individuals
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAOIs (phenelzine, tranylcypromine, linezolid) | Risk of hyperpyretic crisis, severe convulsions, and death due to TCA-like properties; absolute contraindication | High — contraindicated; require 14-day washout |
| SSRIs / SNRIs / tramadol / triptans | Additive serotonergic activity; increased risk of serotonin syndrome | Moderate to high — monitor for agitation, tremor, fever, tachycardia |
| CNS depressants (opioids, benzodiazepines, alcohol) | Additive sedation and respiratory depression; combination with opioids is particularly dangerous | High — avoid or use lowest necessary amounts with close monitoring |
| Anticholinergic drugs (antihistamines, bladder medications, TCAs) | Additive anticholinergic effects: severe dry mouth, urinary retention, constipation, confusion, and risk of paralytic ileus | Moderate — avoid unnecessary combinations especially in elderly |
| Guanethidine / Clonidine | Cyclobenzaprine may block the antihypertensive effects of these medications | Moderate — monitor blood pressure |
| QT-prolonging drugs (certain antipsychotics, antiarrhythmics) | Additive QT prolongation risk due to cyclobenzaprine's TCA-like cardiac effects | Moderate — use cautiously; obtain baseline ECG if indicated |
Warnings & Contraindications
⚠ CONTRAINDICATED with MAOIs or within 14 days of MAOI use. Also contraindicated in the acute recovery phase following myocardial infarction, in patients with arrhythmias or heart block, or in patients with hyperthyroidism. Due to TCA-like cardiac properties, cyclobenzaprine can cause potentially fatal arrhythmias in susceptible individuals.
- Short-term use only: FDA approval is for short-term use (up to 2–3 weeks). Effectiveness beyond this period has not been established and chronic use is associated with ongoing sedation, dependence concerns, and cumulative anticholinergic burden.
- Elderly patients: Cyclobenzaprine is on the Beers Criteria list of potentially inappropriate medications for older adults. Anticholinergic effects (confusion, urinary retention, constipation) and fall risk from sedation make it high-risk in this population. Alternatives should be considered.
- Driving impairment: Cyclobenzaprine causes significant drowsiness. Patients must avoid driving or operating machinery until they know how the drug affects them.
- Hepatic impairment: Cyclobenzaprine is extensively metabolized by the liver. Use with caution in patients with hepatic impairment; levels may accumulate.
- Thyroid disease: Hyperthyroidism increases cardiac sensitivity to TCA-like drugs; avoid in hyperthyroid patients.
FAQ
Does cyclobenzaprine directly relax muscles?
No — this is a common misconception. Cyclobenzaprine does not act on the muscle itself or the neuromuscular junction. Its muscle-relaxing effect is entirely mediated through the central nervous system, particularly the brainstem, where it reduces abnormal motor nerve firing that drives painful muscle spasm. The sedation it causes may independently help by allowing rest and reducing pain-driven muscle guarding.
Why is cyclobenzaprine limited to short-term use?
Clinical trials demonstrated effectiveness over 1–2 weeks for acute muscle spasm. Evidence for benefit beyond 2–3 weeks is lacking, while the anticholinergic and sedative side effects continue or worsen with ongoing use. Additionally, with prolonged use there is potential for tolerance to the muscle-relaxant effect and ongoing impairment of cognitive function and alertness. Physical therapy and active rehabilitation are more appropriate for longer-term musculoskeletal recovery.
Is cyclobenzaprine a controlled substance?
Cyclobenzaprine is not scheduled by the DEA and does not require a controlled substance prescription. However, it does have a potential for misuse — it is sometimes sought for its sedative and euphoric effects, particularly in combination with other CNS depressants. Some states have added it to their prescription drug monitoring programs (PDMPs). Prescribers may exercise caution accordingly.
Can I drink alcohol while taking cyclobenzaprine?
No. Combining alcohol with cyclobenzaprine causes additive CNS depression — significantly amplifying sedation, impairing coordination and judgment, and increasing the risk of accidents. In combination with other CNS depressants, including opioids, the risk extends to dangerous respiratory depression. Alcohol should be completely avoided during cyclobenzaprine treatment.
Need to identify a cyclobenzaprine tablet by its imprint, shape, or color?
Use the PillID Pill Identifier →